Vaezi et al. used quantitative immunohistochemistry to measure ERCC4 expression in tumors from a cohort of 80 patients with newly diagnosed SCCHN treated with radiation therapy with or without platinum-based chemotherapy, and they found that high ERCC4 expression correlated with early time to progression of SCCHN, suggesting that ERCC4 expression levels predict clinical response to DNA damaging agents in SCCHN [26]. Here, ERCC4 is linked to head and neck squamous cell carcinoma.